Literature DB >> 31105995

MicroRNA-874 functions as a tumor suppressor in rhabdomyosarcoma by directly targeting GEFT.

Hao Shang1, Yang Liu1, Zhenzhen Li1, Qianqian Liu1, Wenwen Cui1, Liang Zhang1, Yuwen Pang1, Chunxia Liu1, Feng Li1,2.   

Abstract

MicroRNA-874 (miR-874) is downregulated and acts as a tumor suppressor gene in several human cancers. Its biological function and underlying molecular mechanism in rhabdomyosarcoma (RMS), however, remain unclear. In this study, we found that miR-874 expression was downregulated in human RMS tissue samples and cell lines through quantitative real-time polymerase chain reaction (qRT-PCR). Functional studies revealed that miR-874 overexpression in RMS cells remarkably inhibited proliferation, invasion, migration, and induced apoptosis. The results of luciferase activity assay, qRT-PCR and western blot analyses showed that miR-874 inhibited GEFT translation and suppressed GEFT expression by directly targeting the 3'-untranslated region (3'-UTR) of GEFT mRNA. GEFT expression was upregulated in RMS tissue samples and cell lines and was inversely correlated with miR-874 expression. Downregulation of GEFT has similar effects to miR-874 overexpression in RMS cells. Notably, GEFT restoration partially reversed the tumor-suppressive effects of miR-874. Our results indicated that miR-874 functions as a tumor suppressor in RMS and may suppress the growth and metastasis of RMS cells partially by targeting GEFT.

Entities:  

Keywords:  GEFT; Rhabdomyosarcoma; miR-874

Year:  2019        PMID: 31105995      PMCID: PMC6511638     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  7 in total

Review 1.  MicroRNA Regulation of the Small Rho GTPase Regulators-Complexities and Opportunities in Targeting Cancer Metastasis.

Authors:  Brock A Humphries; Zhishan Wang; Chengfeng Yang
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

2.  Epigenetically upregulated GEFT-derived invasion and metastasis of rhabdomyosarcoma via epithelial mesenchymal transition promoted by the Rac1/Cdc42-PAK signalling pathway.

Authors:  Chunxia Liu; Liang Zhang; Wenwen Cui; Juan Du; Zhenzhen Li; Yuwen Pang; Qianqian Liu; Hao Shang; Lian Meng; Wanyu Li; Lingxie Song; Ping Wang; Yuwen Xie; Yuanyuan Wang; Yang Liu; Jianming Hu; Wenjie Zhang; Feng Li
Journal:  EBioMedicine       Date:  2019-11-21       Impact factor: 8.143

3.  Circular RNA TRAPPC6B inhibits intracellular Mycobacterium tuberculosis growth while inducing autophagy in macrophages by targeting microRNA-874-3p.

Authors:  Hou-Long Luo; Jiang Pi; Jun-Ai Zhang; En-Zhuo Yang; Huan Xu; Hong Luo; Ling Shen; Ying Peng; Gan-Bin Liu; Cai-Mei Song; Ke-Yue Li; Xian-Jin Wu; Bi-Ying Zheng; Hong-Bo Shen; Zheng W Chen; Jun-Fa Xu
Journal:  Clin Transl Immunology       Date:  2021-02-18

4.  Long Non-Coding RNA LINC00355 Promotes the Development and Progression of Colorectal Cancer by Elevating Guanine Nucleotide Exchange Factor T Expression via RNA Binding Protein lin-28 Homolog A.

Authors:  Yuanyuan Wang; Bing Zhang; Ge Gao; Yinping Zhang; Qingxin Xia
Journal:  Front Oncol       Date:  2020-12-14       Impact factor: 6.244

Review 5.  miR-874: An Important Regulator in Human Diseases.

Authors:  Qiudan Zhang; Chenming Zhong; Qianqian Yan; Ling-Hui Zeng; Wei Gao; Shiwei Duan
Journal:  Front Cell Dev Biol       Date:  2022-04-06

6.  Enhancement of myogenic differentiation and inhibition of rhabdomyosarcoma progression by miR-28-3p and miR-193a-5p regulated by SNAIL.

Authors:  Klaudia Skrzypek; Artur Nieszporek; Bogna Badyra; Małgorzata Lasota; Marcin Majka
Journal:  Mol Ther Nucleic Acids       Date:  2021-04-20       Impact factor: 8.886

7.  GEFT Inhibits Autophagy and Apoptosis in Rhabdomyosarcoma via Activation of the Rac1/Cdc42-mTOR Signaling Pathway.

Authors:  Chunsen Li; Zhenzhen Li; Lingxie Song; Lian Meng; Guixuan Xu; Haijun Zhang; Jianming Hu; Feng Li; Chunxia Liu
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.